Afficher la notice abrégée

Contrast-enhanced intra-operative ultrasound as a clinical decision making tool during surgery for colorectal liver metastases: The ULIIS study

dc.rights.licenseopenen_US
dc.contributor.authorDESOLNEUX, G.
dc.contributor.authorISAMBERT, M.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMATHOULIN-PELISSIER, Simone
dc.contributor.authorDUPRE, A.
dc.contributor.authorRIVOIRE, M.
dc.contributor.authorCATTENA, V.
dc.contributor.authorPALUSSIERE, J.
dc.contributor.authorDINART, D.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.contributor.authorEVRARD, S.
dc.date.accessioned2020-06-05T09:28:18Z
dc.date.available2020-06-05T09:28:18Z
dc.date.issued2019-07
dc.identifier.issn0748-7983en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7759
dc.description.abstractEnBACKGROUND: Detecting more colorectal liver metastases (CRLMs) during surgery may help optimise strategy and improve outcomes. Our objective was to determine clinical utility (CU) of contrast-enhanced intra-operative ultrasound (CE-IOUS) using sulphur hexafluoride microbubbles during CRLM surgery. METHOD: A prospective phase II trial performed at two comprehensive cancer research centres. Patients operated for CRLMs were eligible and assessable if intra-operative ultrasound (IOUS) and CE-IOUS had been performed and pathological results were available and/or 3-month imaging. CU was defined as the justified change in planned surgical strategy or procedure using CE-IOUS. RESULTS: Out of the 68 patients enrolled, 54 were eligible and assessable. 43 patients underwent pre-operative chemotherapy. The median number of CRLMs was 2 (range, 1-11). Pre-operative staging was performed using MRI. IOUS allowed identification of 45 new CRLMs in 13 (24.7%) patients. Compared to IOUS, CE-IOUS allowed identification of 10 additional CRLMs in 9 (16.7%) patients. Surgery was altered and justified in 4 patients only, leading to a CU rate of 7.70% (95 CI, [3.2, 18.6]). No missing CRLMs were identified by CE-IOUS. CONCLUSIONS: Although the primary endpoint was not met for one protocol violation, secondary endpoints indicate that CE-IOUS has an intermediate added-value for surgeons treating CRLMs. TRIAL REGISTRATION: NCT01880554 (https://clinicaltrials.gov/).
dc.language.isoENen_US
dc.subject.enEPICENE
dc.title.enContrast-enhanced intra-operative ultrasound as a clinical decision making tool during surgery for colorectal liver metastases: The ULIIS study
dc.title.alternativeEur J Surg Oncolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.ejso.2019.03.002en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30879929en_US
bordeaux.journalEJSO - European Journal of Surgical Oncologyen_US
bordeaux.page1212-1218en_US
bordeaux.volume45en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03209393
hal.version1
hal.date.transferred2021-04-27T08:51:18Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=EJSO%20-%20European%20Journal%20of%20Surgical%20Oncology&rft.date=2019-07&rft.volume=45&rft.issue=7&rft.spage=1212-1218&rft.epage=1212-1218&rft.eissn=0748-7983&rft.issn=0748-7983&rft.au=DESOLNEUX,%20G.&ISAMBERT,%20M.&MATHOULIN-PELISSIER,%20Simone&DUPRE,%20A.&RIVOIRE,%20M.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée